Literature DB >> 16369986

Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters.

Koichi Isobe1, Takashi Uno, Jun-ichi Tamaru, Hiroyuki Kawakami, Naoyuki Ueno, Hisashi Wakita, Jun-ichi Okada, Jun Itami, Hisao Ito.   

Abstract

BACKGROUND: The objective of this study was to investigate the correlation between local recurrence and radiotherapeutic parameters, including dose and RT radiotherapy (RT) field.
METHODS: The current study included 35 patients who were diagnosed with immunohistochemically confirmed nasal natural killer (NK)/T-cell lymphoma between 1976 and 2004. There were 21 males and 14 females, and they ranged in age from 18 years to 76 years (median, 51 yrs). The primary tumor originated in the nasal cavity in 28 patients, and 32 patients had Stage I disease. Seventeen patients received treatment solely with RT, and the remaining 18 patients received a combination of chemotherapy and RT. The median tumor dose was 50 grays (Gy) (range, 22-60 Gy). Twenty-seven patients received RT to include all macroscopic lesions, all paranasal sinuses, the palate, and the nasopharynx. Eight patients received RT to all macroscopic lesions with generous margins.
RESULTS: A complete remission (CR) or a CR/unconfirmed was achieved in 28 patients (80%). The 5-year overall survival (OAS) rate, disease-free survival (DFS) rate, and local control probability (LCP) were 47.3%, 42.9%, and 65.2%, respectively. Patients who received RT only to macroscopic lesions fared less well in terms of LCP (LCP 5 years, 71.9% vs. 41.7%; P=0.007). The difference in RT field also affected both the OAS rate and the DFS rate. Patients who received RT doses>or=50 Gy tended to achieve favorable local control.
CONCLUSIONS: In the management of nasal NK/T-cell lymphoma, the RT field affected treatment outcomes. RT doses>or=50 Gy resulted in favorable local control. Copyright (c) 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2006        PMID: 16369986     DOI: 10.1002/cncr.21656

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

2.  Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.

Authors:  Paola Ghione; Shunan Qi; Brandon S Imber; Venkatraman Seshan; Alison Moskowitz; Natasha Galasso; Matthew Lunning; David Straus; Craig Sauter; Parastoo Dahi; Ahmet Dogan; Joachim Yahalom; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2020-08-26

3.  Management of NK/T-Cell Lymphoma, Nasal Type.

Authors:  Pamela B Allen; Mary Jo Lechowicz
Journal:  J Oncol Pract       Date:  2019-10       Impact factor: 3.840

4.  Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma.

Authors:  Hong-Qiang Guo; Lei Liu; Xin-Feng Wang; Tong-Yu Lin; Shu-Na Yao; Zhi-Hua Yao; Shu-Jun Yang
Journal:  Mol Clin Oncol       Date:  2014-08-01

5.  Extra-nodal natural killer/T cell lymphoma, nasal-type, treated by concurrent chemoradiotherapy.

Authors:  Nobuhiko Yoshikawa; Taisuke Inomata; Taiju Shinbo; Masatsugu Takahashi; Yasuo Uesugi; Yoshihumi Narumi
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

6.  Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience.

Authors:  Yukiko Hattori; Taro Murai; Hiromitsu Iwata; Kaoru Uchiyama; Mikio Mimura; Eriko Kato; Rumi Murata; Yuta Shibamoto
Journal:  Jpn J Radiol       Date:  2016-02-06       Impact factor: 2.374

Review 7.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

Review 8.  Current and future management of NK/T-cell lymphoma based on clinical trials.

Authors:  Motoko Yamaguchi
Journal:  Int J Hematol       Date:  2012-10-17       Impact factor: 2.490

9.  An extranodal NK/T cell lymphoma, nasal type, with specific immunophenotypic and genotypic features.

Authors:  Panagiotis Katsaounis; Alexandra Alexopoulou; Spyros P Dourakis; Alexandros Smyrnidis; Leonidas Marinos; Anna Filiotou; Athanasios J Archimandritis
Journal:  Int J Hematol       Date:  2008-07-25       Impact factor: 2.490

10.  Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group.

Authors:  Tao Wu; Yong Yang; Su-Yu Zhu; Mei Shi; Hang Su; Ying Wang; Xia He; Li-Ming Xu; Zhi-Yong Yuan; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Jun-Xin Wu; Chen Hu; Shu-Nan Qi; Bo Chen; Ye-Xiong Li
Journal:  Blood Adv       Date:  2018-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.